Navigation Links
Treating Blocked Arteries In The Lower Limbs

Lower extremity ischemia, or abnormal circulation, occurs when arteries in the abdomen or pelvis narrow or become completely blocked // by the build-up of plaque deposits. As a result, not enough oxygen-rich blood gets to the legs, causing cramps and pain, and making it difficult to walk or exercise. The iliac arteries are large arteries in the pelvis that supply blood to the legs.

Researchers say, stent placement should be considered the standard of care for treating patients with abnormal circulation due to the obstruction of the iliac arteries. Analyzing available data, the investigators found blood circulation improved with stents in 484 limbs out of 496 limbs of patients suffering from chronic leg ischemia. After five years, 86 percent of stented vessels remained open. After eight years, 84 percent remained open.

A growing number of interventional radiologists are treating the condition with a less invasive stenting procedure. With this procedure, a catheter, or thin flexible tube, is inserted through a small incision in the skin and threaded to the site of the blocked artery. The vessel is pumped open by a tiny balloon, and the stent is inserted to hold open the blood vessel. Until the stent was introduced 10 years ago, the only way to open up such vessels was surgically bypassing the blockage with a healthy vein or artery.
'"/>




Page: 1

Related medicine news :

1. Treating eye pain eases migraine
2. Treating wounds without stitches
3. Treating varicose veins
4. Treating acne with laser
5. Once-Daily Cipro(R) XR for Treating Complicated Urinary Tract Infections
6. Treating Stroke Patients in Rural Areas
7. Free Tissue Transfer Effective in Treating Massive Skin Cancers
8. Zinc Supplements Found To Be Effective In Treating Children With ADHD
9. Hormone Leptin Found To Be Effective In Treating Women With Infertility Problems
10. Treating Depression In Children Could Lead To Poor Bone Development
11. The Effect Of Pain Relievers In Treating Kids With Migraine Questioned
Post Your Comments:
(Date:5/16/2008)...cal trials presented by Calpis Co., Ltd. at the Am...Annual Scientific Meeting and Exposition (ASH 2008...y supplement AmealPeptide reduces blood pressure i...D (Achieve Hypertension Efficacy with AmealPeptide...tive, Two-phase Randomized, Open-Label, Blinded En...
(Date:5/16/2008)... -- Superior launch strategies,allow best-in-class...,crowded markets. To secure "share of voice" for a...ptake strategies to support business needs and,ens...l companies achieve,attention in the market during...., "Best Practices for Winning Product Launch Suc...
(Date:5/16/2008)...d Information Technology That, Optimizes Cardiolo...ases Efficiency, SE...ced clinical and,information technology (IT) for t...www.siemens.com/healthcare ) will demonstrate the ...iology and cardiology workflow and image,processin...
(Date:5/16/2008)...PRNewswire-FirstCall/ -- BMP,Sunstone Corporation ...and,distribution pharmaceutical companies, today a...owing conferences:, (1) The Roth Annual China D...David Gao, Chief Executive Officer of the Company,... 2008, at 4:40 pm local time at the Regent Ho...
Breaking Medicine News(10 mins):Health News:Calpis' AmealPeptide lowers blood pressure in 2 placebo-controlled trials 2Health News:Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes 2Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 2Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 3Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 4Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 5Health News:BMP Sunstone Announces Participation in May Investor Conferences 2
...ts may be beneficial in preventing severe long-ter...resently there exists no effective treatment for t...isability is most likely to appear. The Children...ing in the Journal of Neuroscience, and conducted...
...C, Wednesday to demand more funds for cancer resea...traveled to the rally in Washington.// She said, "...hes so many people, but on the other hand, it's em...eople willing to volunteer, give their time and th...
...nesday reported having updated the warning label o...sers about the higher risk of blood clots from it....missioned study revealed that drug users faced two... lungs compared to women taking traditional birth-...
...rpose of a sunscreen lotion as well as offers prot...searchers//, well on the threshold of a discovery;...athway that will prevent the fair skin people from...ainst cancer. Study's lead author, Dr. David E. F...
Other Medicine News:Health News:Vitamin Shots to Combat MS Pain 2Health News:Contraceptive Patch Carries Risk of Blood clots 2
(Date:5/16/2008)...Newswire-FirstCall/ -- Pulmo BioTech Inc. (OTC,Bul... methodology and,purpose of its Phase I Human Tria... for the diagnosis of Pulmonary Embolism and Pulmo...by the Pulmo BioTech subsidiary,PulmoScience Inc....the Use,of PulmoBind for Molecular Imaging of the ...
(Date:5/16/2008)...ay 16 /- Data from three studies,eval...moglobin (Hb) levels,and the rate of blood transfu...ons on reimbursement for erythropoiesis-stimulatin...,s blood supply, will be presented at the,American...g later this,month. The meeting will take place in...
(Date:5/16/2008)...bles First-Ever PEGylation of a Small Molecule wit...ity, SAN CARLOS, Calif., May 16 /PRNewswire-First...unced initial results today from a Phase 1,study o...significant,anti-tumor activity in patients with r...s that Nektar,s small molecule PEGylation technolo...
(Date:5/16/2008)...Dual Mechanism May Offer Novel Approach to Blood ...ORLEANS, May 16 /- Pharmaco... and development of novel small,molecule therapeut...lass,Dual Acting Receptor Antagonist (DARA), showe...ons in a Phase 2a study in patients with mild to,m...
Breaking Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Alticors 2007 Global Sales Top 247 Billion 11136 1Alticors 2007 Global Sales Top 247 Billion 11136 2Alticors 2007 Global Sales Top 247 Billion 11136 3Alticors 2007 Global Sales Top 247 Billion 11136 4Alticors 2007 Global Sales Top 247 Billion 11136 5Alticors 2007 Global Sales Top 247 Billion 11136 6Shengtai Pharmaceutical Inc Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 3072 1Shengtai Pharmaceutical Inc Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 3072 2Shengtai Pharmaceutical Inc Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 3072 3AstraZeneca Gives 241 5 million to Support North Carolina Worksite Wellness Project 11133 1AstraZeneca Gives 241 5 million to Support North Carolina Worksite Wellness Project 11133 2AstraZeneca Gives 241 5 million to Support North Carolina Worksite Wellness Project 11133 3HMS Holdings Corp Hosts Fourth Quarter and Full Year 2007 Financial Teleconference and Presentation 11130 1HMS Holdings Corp Hosts Fourth Quarter and Full Year 2007 Financial Teleconference and Presentation 11130 2
...SS WIRE)--Jul 9, 2007 - ZIOPHARM,Oncology, Inc. (N...from an ongoing phase II trial of ZIO-201 (isophos... patients was presented at the,European Society of...07 in Lugano, Switzerland. The abstract entitled, ...coma," was presented by,Rashmi Chugh, MD, a Princi...
...--Jul 9, 2007 - TransPharma Medical,Ltd., a specia...ent,and commercialization of drug products utilizi...technology, announced today,promising results of i...y and pharmacokinetic profile of its ViaDerm-hPTH ... A seven day, repeated dose application, parallel ...
Other Medicine Technology:Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 2TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 3
We have water perfused manometric catheters for esophageal, anorectal and vector volume diagnostic tests. All Medtronic Water Perfused Catheters are made using clear, medical grade PVC tubing. For pr
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator.
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator.
...dtronic offers a family of single-use products to ...or you. This single-use catheter reduces cross-con...e risk of infection and, because cleaning is elimi...have water perfused manometric catheters for esoph...
Medicine Products: